EBOVAC2-related publications

Wagstaffe, HR; (2019) The Effect of Viral Vaccines on Natural Killer Cell Effector Function. PhD (research paper style) thesis, London School of Hygiene & Tropical Medicine. DOI: https://researchonline.lshtm.ac.uk/id/eprint/4653621/



7th EBOVAC2 Newsletter

Find out the news from the project in November 2017 here - with the announcement of the Ebovac2 4th General annual meeting planned in Nairobi (Kenya) next January.


6th EBOVAC2 Newsletter

Latest news from the project and interview with Dr Hervé Raoul, Director of Inserm's BSL-4 laboratory.


5th EBOVAC2 Newsletter

Find out what's going on in EBOVAC2, with a special focus on the Burkina Faso training session in January 2018. 


4th EBOVAC2 Newsetter 

News on EBOVAC2 December 2017, click here.


3rd EBOVAC2 Newsletter 

News on EBOVAC2 in October 2017 click here. This issue includes an interview with Dr Houreratou Barry, PI of the Centre Muraz clinical site.


2nd EBOVAC2 Newsletter 

Find out what's going on in EBOVAC2 here in June 2017.


1st EBOVAC2 Newsletter 

Get a view on the EBOVAC2 news here in March 2016.


  • 23 April 2019

    An Ebovac2 poster was selected among 13 out of approx. 2 500 posters on the top rated of the ECCMID 2019. To view the poster, please, click here. Congratulations to the authors!

  • 24 September 2018

    The 7th newsletter is available here. This issue announces Ebovac2 4th annual meeting in Nairobi (Kenya) in January 2019. 

  • 12 September 2017

    The 3rd EBOVAC1/2 Annual meeting will be held in Amsteram, the Netherlands 8-10 January 2018. Participants include consortium members and representatives of sites where the project clinical trials are being carried out.

  • 15 May 2017

    Based on final Phase 1 data published in JAMA: The Journal of the American Medical Association, the prime-boost Ebola vaccine regimen induced an antibody response that persisted in 100 percent of healthy volunteers to at least 1 year following vaccination. The results are from the EBOVAC1 study EBL1001 conducted by the Oxford Vaccine Group in the UK.

  • 15 May 2017

    Victoria Derbyshire reporter Catrin Nye went to visit the Oxford Vaccine Group looking for volunteers who participated in the EBL2001 study. Prof. Andrew Pollard (Professor of Paediatric Infection and Immunity and Oxford Vaccine Group PI for EBOVAC1 and EBOVAC2 ) and study volunteers were interviewed.Watch here : http://www.bbc.co.uk/news/uk-39202974

  • 13 November 2016

    The joint EBOVAC1 and EBOVAC2 annual meeting took place in Windsor, UK from 14-16 November 2016.

More news
  • Ebola: background

    What is Ebola?

  • Phase 2 trials

    Find out more about EBOVAC2 trials

  • Work programme

    EBOVAC2 is organised into 6 workpackages (WP)

  • Ebola+ programme

    Contributes to efforts to tackle a wide range of challenges in Ebola research